<p>In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: </p><p>1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. <a href="https://pubmed.ncbi.nlm.nih.gov/38828933/">https://pubmed.ncbi.nlm.nih.gov/38828933/<br></a><br></p><p>2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. <a href="https://pubmed.ncbi.nlm.nih.gov/38828951/">https://pubmed.ncbi.nlm.nih.gov/38828951/<br></a><br></p><p>3. Long-term follow-up of CASSIOPEIA Trial: <a href="https://pubmed.ncbi.nlm.nih.gov/38889735/">https://pubmed.ncbi.nlm.nih.gov/38889735/<br></a><br></p><p>4. Update on MRD data from PERSEUS Trial: <a href="https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7502">https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7502<br></a><br></p>

Blood Cancer Talks

Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach

NOV 13, 202444 MIN
Blood Cancer Talks

Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach

NOV 13, 202444 MIN

Description

In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 

1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/

2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828951/

3. Long-term follow-up of CASSIOPEIA Trial: https://pubmed.ncbi.nlm.nih.gov/38889735/

4. Update on MRD data from PERSEUS Trial: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7502